Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 25-year-old man with myasthenia gravis and a non-Hodgkin lymphoma stage III B involving the thymus, is reported. The association myasthenia gravis and non-Hodgkin lymphoma has not been described previously. Treatment with chlormetin, vincristine, procarbazine, prednisone (MOPP) resulted in complete remission of both the myasthenic symptoms and the malignant lymphoma.
 ...
PMID:A case of malignant lymphoma and myasthenia gravis. 631 Jul 30

In the mouse, retrovirus B and C are causal agents of mammary cancer and leukemia, respectively. In previous work it was demonstrated that sera of leukemia-lymphoma patients possess antibodies which react with antigenic determinants of Type C virus present on AKR-lymphoma and AKR-thymus targets. The object of this paper was to determine whether these antibodies also reacted with Type B viral antigens present on a virus-induced BALB-mammary carcinoma; at the same time a comparative study was carried out with sera of breast cancer patients. A total of 325 sera were obtained from 277 leukemia-lymphoma cases under protocol treatment: 232 acute lymphoid leukemia, 23 acute myeloid leukemia, 15 chronic myeloid leukemia and 55 Hodgkin lymphoma sera. A total of 240 sera were obtained from breast cancer patients at the time of diagnosis and 196 sera from normal blood donors served as controls. Using indirect immunofluorescence with labeled anti-human IgG and the murine targets, antibodies were encountered in a high percentage of cancer cases and were consistently absent in normal sera. The results confirm the presence of antibodies reacting with murine Type C virus in leukemia-lymphoma cases and indicate the presence of antibodies reacting to both Type B and C retroviruses in the sera of breast cancer patients.
 ...
PMID:Antibodies presumably cross-reacting with mouse retrovirus type B and C in the sera of both leukemia-lymphoma and mammary cancer patients. 631 22

The incorporation of ATP on poly(A) primers catalyzed by poly(A) polymerase was investigated in normal and neoplastic lymphoid cells from animal and human sources. High levels of the enzyme were found in mouse thymus, in chicken bursa and thymus, as well as in neoplastic cells from patients affected by lymphoblastic and Burkitt's lymphomas. Low or very low quantities were found in peripheral blood lymphocytes, chronic lymphocytic leukemia cells, normal lymph nodes and solid lymphoid tissues of Hodgkin's disease. In general, the enzymatic content of neoplastic lymphoid cells reflected those of their normal counterpart. No effect of fasting or cortisone treatment on poly(A) polymerase in mouse spleen, thymus or liver was found. No particular relationships with B, T or non-T, non-B lineages were observed, but some relationship with DNA polymerase alpha was found. Therefore, it may be that poly(A) polymerase levels are related to the proliferative activity of the cellular populations.
 ...
PMID:Poly(A) polymerase distribution in normal and malignant lymphoid cells. 632 15

Patients with Hodgkin's disease manifest decreased percentage of E rosette-forming (T) lymphocytes in the peripheral blood. We have investigated thymosine-like factor in peripheral blood lymphocytes in these patients by immunofluorescence method. Some of lymphocytes showed the excess of thymosine-like factor. The addition of antiserum to thymus factor increased percentage of E rosette-forming (T) lymphocytes in the peripheral blood in Hodgkin's disease.
 ...
PMID:In vitro stimulation of T-cell rosette formation by antiserum to thymus factor in Hodgkin's disease. 633 94

Natural killer (NK) cells have been implicated in natural resistance to tumours, particularly lymphomas. Recently, they have been implicated in the regulation of human erythropoiesis. The distribution of NK cells in peripheral lymphoid tissues has not been fully documented. NK activity in human or murine lymph nodes is significantly lower than in the spleen or peripheral blood. In Hodgkin's disease, affected lymph nodes and spleens have higher NK activity than non-involved nodes or spleens. Using a monoclonal antibody (Leu 7) that defines the human NK antigen HNK-1 (ref. 8), only a small number of HNK-1+ cells were found in lymph nodes, tonsils or thymus, with greater numbers in the spleen. We report here the topographical distribution of HNK-1+ cells in normal human lymph nodes, tonsils and spleen and preliminary observations in various forms of malignant lymphoma. The most striking observation was that HNK-1+ cells were not distributed uniformly in these tissues but specifically localized in the B-cell compartments (follicular centres).
 ...
PMID:Natural killer-like cells found in B-cell compartments of human lymphoid tissues. 634 8

Terminal deoxynucleotidyl transferase (TdT) is a unique DNA-polymerase which is restricted to a few organs (thymus, bone marrow and blood). Therefore, the enzyme is suited for the role of a tumor marker in all other organs. The immunohistological demonstration, hitherto, was mainly hampered by the lack of potent and specific antibodies and by the readiness of the enzyme to diffuse. Now, these problems are solved. The immunohistological demonstration of TdT can be used to classify acute leukemias and lymphoblastic non-Hodgkin-lymphomas of children and to early recognize relapse situations.
 ...
PMID:[Demonstration of terminal deoxynucleotidyl transferase in histological sections]. 634 96

An unusual case of classic thymic granuloma is reported. A 16-year-old boy presented with a huge mediastinal mass and the superior vena caval syndrome. Irradiation and combination chemotherapy induced complete remission, despite several episodes of lymph node recurrence. Examination of the first biopsy specimen was considered to indicate a histiocytic tumor or malignant form of eosinophilic granuloma, because of the diffuse proliferation of histiocytes and marked infiltration of eosinophils. Late involvement in the lymph node appeared to have the same histologic characteristics as the mediastinal tumor. Immunohistochemically, the proliferating histiocytes were stained with anti-S100 protein IgG but not with anti-lysozyme or anti-NCA (nonspecific cross-reacting antigen with carcinoembryonic antigen) antibody. These characteristics were similar to those of interdigitating cells in the lymph nodes, thymus, and other lymphoid tissues. The relationship of this case to mediastinal Hodgkin's disease or proliferative disorders of histiocytes is discussed.
 ...
PMID:A case of large "thymic granuloma". Neoplasm of T-zone histiocyte. 649 38

The effect of the calf thymus extract thymustimulin (Tp-1) on lymphocyte subpopulations of 12 patients affected by lymphoproliferative disorders with low T-cell level was studied. T and B cells of four patients with non-Hodgkin lymphoma, three with Hodgkin's disease, one with myeloma and four with chronic lymphatic leukemia were evaluated before and after treatment for 3 months with Tp-1. The total number and the percentage of T-cells increased significantly (p less than 0.05) in patients with non Hodgkin lymphoma, Hodgkin's disease and myeloma and only numerically in patients with chronic lymphatic leukemia, while no significant change of the total WBC count and of the total number and percentage of B-cells occurred in any patients. These results suggest that Tp-1 treatment might be effective in restoring immunocompetence in patients with T-cell deficiency secondary to lymphoproliferative disorders.
 ...
PMID:Effect of treatment with thymustimulin (Tp-1) on T and B cells in lymphoproliferative disorders. 660 85

The in vivo effect of a calf thymus extract, thymostimulin, on the levels of circulating immune complexes (CIC) and serum lysozyme was evaluated in 32 patients with untreated Hodgkin's disease. Using the platelet aggregation test for detecting CICs, 12 patients (37%) had positive titers before thymostimulin treatment; 3 patients (10%) remained positive following therapy. Serum levels of Clq-binding immune complexes were evaluated (greater than 24.5 micrograms/ml) in 8 patients prior to thymostimulin therapy (mean value: 42.3 micrograms/ml); 3 patients continued to have elevated levels after treatment. Serum lysozyme levels for Hodgkin's patients was similar to control values (10.6 vs. 8.3 micrograms/ml); however, the Hodgkin's patients with initially elevated CICs had a lower serum lysozyme level than patients with initially normal CICs (12.9 vs. 7.3, p less than 0.02). Thymostimulin increased serum lysozyme levels in the Hodgkin's patients in whom the CICs were initially elevated (7.3 vs. 10.4 micrograms/ml, p less than 0.05). These data suggest that thymostimulin exerts an effect on the nonspecific immune system of Hodgkin's disease patients.
 ...
PMID:The in vivo effect of thymic factor (thymostimulin) administration on circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease patients. 666 95

Clinical, morphological, cytochemical and immunological features in a case of T-lymphoma in a 67-year-old man are presented. Clinically, a predilection for lymph nodes was observed with a subsequent tumour-like spread to the liver, lungs and, to a minor extent, to the bone marrow. The skin, the spleen and the thymus were spared. Morphologically, the neoplastic lymphoid cells were characterized by their large size and particularly by their hypersegmented nuclei with a relatively coarse chromatin and large nucleoli. Cytochemically, a T-cell-like staining pattern in the acid phosphatase and in the acid alpha-naphthyl acetate esterase stains was absent. The neoplastic lymphocytes demonstrated a strong binding with sheep erythrocytes in suspension and in cryostat tissue sections. The morphological features of this lymphoma appear distinct from other non-Hodgkin's lymphomas. The similarities and the differences of our case in relation to some recently described cases of peripheral T-lymphomas comprising large cells with hyperlobated nuclei, are discussed.
 ...
PMID:Large-cell T-lymphoma with hypersegmented nuclei. 697 Apr 8


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>